Physician

Amy D Mcmullen, M.D.

According to 2025 Medicare claims, Amy Mcmullen, M.D. (NPI: 1205860954) practices medical oncology in the Santa Cruz-Watsonville, CA market, with the plurality of this provider's patient population coming from Santa Cruz, CA. This provider's primary affiliated billing organization is CENTRAL COAST ONCOLOGY & HEMATOLOGY (NPI: 1942473491; TIN: 26-2070979) and primary practice location at 95065-0001.

Mcmullen's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 468 traditional Medicare patients, billed 265,497 HCPCS/CPT codes, and received $5,812,468 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,481 prescription claims across 239 beneficiaries totaling $4,305,577 in drug costs, led by Pomalyst (Pomalidomide). DME data shows 11 claims. Open Payments data shows 139 records totaling $3,460. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $1,540,257 to $5,812,468. Similarly, Part D prescription costs have moved sharply higher in recent years, from $352,791 to $4,305,577. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $12,849 to $5,989.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	329	112,990	$1,540,257
2016	323	112,248	$1,891,128
2017	337	101,614	$2,293,142
2018	437	175,172	$3,128,554
2019	485	214,776	$3,504,363
2020	440	201,164	$3,971,784
2021	486	184,616	$3,577,602
2022	496	234,510	$4,136,837
2023	471	291,091	$6,820,111
2024	468	265,497	$5,812,468

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	132	1,008	$352,791
2016	158	1,344	$773,210
2017	156	1,332	$1,576,853
2018	174	1,238	$1,721,763
2019	207	1,349	$2,133,077
2020	181	1,217	$1,988,839
2021	207	1,295	$2,276,413
2022	218	1,439	$3,007,896
2023	244	1,566	$3,669,178
2024	239	1,481	$4,305,577

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	127	$24,908
2016	N/R	80	$50,580
2017	12	113	$53,836
2018	N/R	109	$2,319
2019	N/R	56	$5,335
2020	N/R	N/R	N/R
2021	N/R	12	$130
2022	N/R	41	$855
2023	N/R	64	$5,107
2024	N/R	11	$207

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	145	249	$149
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	356	840	$104
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	142	933	$74
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	182	235	$13
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	169	1,138	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	75	2,100	$1,645,048
Ibrance	Palbociclib	27	756	$414,667
Venclexta	Venetoclax	33	1,254	$260,524
Revlimid	Lenalidomide	19	406	$229,452
Imbruvica	Ibrutinib	14	392	$228,647

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	11	$207

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	139	$3,460	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Amy D. Mcmullen, M.D.?

Tedicare shows public-source Medicare data for Amy D. Mcmullen, M.D. (NPI 1205860954), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Amy D. Mcmullen, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Amy D. Mcmullen, M.D.?

Amy D. Mcmullen, M.D. is linked to CENTRAL COAST ONCOLOGY & HEMATOLOGY (billing NPI 1942473491) in the available physician profile data.

Does Amy D. Mcmullen, M.D. have Open Payments data?

Amy D. Mcmullen, M.D. has 139 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.